Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Sees Unusually High Call Option Buying

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of unusually large options trading activity on Monday. Stock traders acquired 32,589 call options on the company. This represents an increase of 79% compared to the typical daily volume of 18,227 call options.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Najat Khan sold 22,408 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the sale, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $3.34, for a total transaction of $100,200.00. Following the completion of the transaction, the director owned 6,158,287 shares of the company’s stock, valued at $20,568,678.58. This represents a 0.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 122,408 shares of company stock worth $434,976. 6.65% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ascent Wealth Partners LLC increased its stake in shares of Recursion Pharmaceuticals by 11.8% during the first quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock worth $86,000 after acquiring an additional 2,974 shares during the period. Cherry Creek Investment Advisors Inc. boosted its holdings in Recursion Pharmaceuticals by 5.8% in the 1st quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company’s stock valued at $217,000 after purchasing an additional 3,859 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Recursion Pharmaceuticals by 33.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,832 shares of the company’s stock valued at $52,000 after purchasing an additional 4,199 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in Recursion Pharmaceuticals by 51.5% during the 1st quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after purchasing an additional 5,156 shares during the period. Finally, Axxcess Wealth Management LLC increased its position in Recursion Pharmaceuticals by 16.6% during the 1st quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company’s stock worth $115,000 after purchasing an additional 5,338 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Finally, Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a research report on Monday, August 17th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.06.

Recursion Pharmaceuticals Stock Up 14.2%

RXRX stock traded up $0.59 during midday trading on Monday, reaching $4.71. 40,853,578 shares of the company were exchanged, compared to its average volume of 18,488,717. The company has a market cap of $2.52 billion, a price-to-earnings ratio of -4.54 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $7.18. The stock’s 50-day simple moving average is $3.43 and its 200 day simple moving average is $3.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The company had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. During the same period last year, the business earned ($0.41) earnings per share. On average, equities analysts forecast that Recursion Pharmaceuticals will post -0.94 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.